{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:18:41Z","timestamp":1760235521638,"version":"build-2065373602"},"reference-count":46,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>T-cell specificity can be redirected against tumor antigens either ex vivo using engineered chimeric antigen receptor (CAR) T-cells or in vivo by bridging natural T-cells and tumor cells with bispecific T-cell engager (TCE) antibodies. Currently, four CAR T-cells have been approved by the FDA for the treatment of B-cell lymphomas, including diffuse large B cell lymphomas (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). No TCE have yet been approved for the treatment of B-cell lymphomas. However, at least four of them are in clinical development and show promising activity. Here, we review the most recent advances of CAR T-cells and TCE in the treatment of B-cell lymphomas.<\/jats:p>","DOI":"10.3390\/cancers13174274","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:19:26Z","timestamp":1629937166000},"page":"4274","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances"],"prefix":"10.3390","volume":"13","author":[{"given":"Ondine","family":"Mess\u00e9ant","sequence":"first","affiliation":[{"name":"Department of Hematology, University Hospital of Rennes, 35000 Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital of Rennes, 35000 Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Manson","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital of Rennes, 35000 Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-137045","article-title":"Myc expression and tumor-infiltrating T cells are associated with response in patients (Pts) with relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL) treated with tisagenlecleucel in the juliet trial","volume":"136","author":"Jaeger","year":"2020","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Jacobson, C.A., Locke, F.L., Ghobadi, A., Miklos, D.B., Lekakis, L.J., Oluwole, O.O., Lin, Y., Braunschweig, I., Hill, B.T., and Timmerman, J.M. (2020, December 05). Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel). Available online: https:\/\/www.cancernetwork.com\/view\/axi-cel-induces-long-term-disease-control-in-large-b-cell-lymphoma.","DOI":"10.1182\/blood-2020-134362"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.681984","article-title":"A deep insight into CAR-T cell therapy in non-hodgkin lymphoma: Application, opportunities, and future directions","volume":"12","author":"Marofi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2019-124750","article-title":"Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B Cell lymphoma (LBCL) in the United States (US)","volume":"134","author":"Pasquini","year":"2019","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fonc.2020.00849","article-title":"CAR T-cell therapy for B-cell non-hodgkin lymphoma and chronic lymphocytic leukemia: Clinical trials and real-world experiences","volume":"10","author":"Vitale","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1200\/EDBK_279043","article-title":"ADCs, BiTEs, CARs, and small molecules: A new era of targeted therapy in non-Hodgkin lymphoma","volume":"40","author":"Abramson","year":"2020","journal-title":"Am. Soc. Clin. Oncol Educ. Book"},{"key":"ref_16","unstructured":"Kite (2021, June 28). Yescarta\u00ae CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma. Available online: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2021\/6\/kite-announces-yescarta-car-tcell-therapy-improved-eventfree-survival-by-60-over-chemotherapy-plus-stem-cell-transplant-in-secondline-relapsed-or."},{"key":"ref_17","unstructured":"Bristol-Myers Squibb Company (2021, June 10). Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (Lisocabtagene Maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma. Available online: https:\/\/www.businesswire.com\/news\/home\/20210610005259\/en\/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Phase-3-TRANSFORM-Trial-Evaluating-Breyanzi-lisocabtagene-maraleucel-Versus-Chemotherapy-Followed-by-Stem-Cell-Transplant-in-Second-line-."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Neelapu, S.S. (2020, January 5\u20138). Interim analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients (Pts) with high-risk large B cell lymphoma (LBCL). Proceedings of the 62nd ASH Annual Meeting and Exposition, ASH, San Diego, CA, USA.","DOI":"10.1182\/blood-2020-134449"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"TPS7585","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7585","article-title":"ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed\/refractory diffuse large B cell lymphoma (R\/R DLBCL)","volume":"36","author":"Oluwole","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-136640","article-title":"Outcomes of treatment with the chimeric antigen receptor (CAR) T cell therapy lisocabtagene maraleucel (lisocel) in the nonuniversity setting: Initial results from the Outreach study","volume":"136","author":"Godwin","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wang, M.L., Munoz, J., Goy, A.H., Locke, F.L., Jacobson, C.A., Hill, B.T., Timmerman, J.M., Holmes, H., Jaglowski, S., and Flinn, I.W. (2020, December 05). One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed\/Refractory Mantle Cell Lymphoma. Available online: https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper136382.html.","DOI":"10.1182\/blood-2020-136382"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Palomba, M.L., Gordon, L.I., Siddiqi, T., Abramson, J.S., Kamdar, M., Lunning, M.A., Maloney, D.G., Andreadis, C., Arnason, J.E., and Ghosh, N. (2020, December 05). Safety and Preliminary Efficacy in Patients with Relapsed\/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001. Available online: https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper136158.html.","DOI":"10.1182\/blood-2020-136158"},{"key":"ref_25","first-page":"40","article-title":"Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed\/Refractory (R\/R) Indolent Non-Hodgkin Lymphoma (iNHL)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1200\/JCO.2021.39.15_suppl.7548","article-title":"Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5","volume":"39","author":"Chavez","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-138983","article-title":"Efficacy and safety of tisagenlecleucel in adult patients with relapsed\/refractory follicular lymphoma: Interim analysis of the phase 2 elara trial","volume":"136","author":"Fowler","year":"2020","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2021.39.15_suppl.7508","article-title":"Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed\/refractory follicular lymphoma (r\/r FL): Primary analysis of the phase 2 Elara trial","volume":"39","author":"Schuster","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Plaks, V., Rossi, J.M., Chou, J., Wang, L., Poddar, S., Han, G., Wang, Z., Kuang, S.-Q., Chu, F., and Davis, R.E. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood, 2021.","DOI":"10.1182\/blood.2021010930"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat. Med."},{"key":"ref_31","first-page":"600","article-title":"Phase 1 alexander study of AUTO3, the first CD19\/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed\/refractory (r\/r) DLBCL","volume":"136","author":"Ramakrishnan","year":"2020","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2020.38.15_suppl.8002","article-title":"First-in-human data of ALLO-501 and ALLO-647 in relapsed\/refractory large B-cell or follicular lymphoma (R\/R LBCL\/FL): ALPHA study","volume":"38","author":"Neelapu","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1200\/JCO.2021.39.15_suppl.7516","article-title":"Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed\/refractory (r\/r) CD19+ NHL","volume":"39","author":"Shah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2020.00888","article-title":"The advent of CAR T-cell therapy for lymphoproliferative neoplasms: Integrating research into clinical practice","volume":"11","author":"Cerrano","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-hodgkin lymphoma: Final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2018-99-112280","article-title":"Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin","volume":"132","author":"Coyle","year":"2020","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-Cell lymphoma: A phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136659","article-title":"Odronextamab (REGN1979), a human CD20 \u00d7 CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-hodgkin lymphoma, including patients refractory to CAR T therapy","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1200\/JCO.2021.39.15_suppl.7518","article-title":"Subcutaneous epcoritamab in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity","volume":"39","author":"Clausen","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-136255","article-title":"Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma","volume":"136","author":"Olszewski","year":"2020","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-136044","article-title":"Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-133820","article-title":"Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed\/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: Updated dose escalation data","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4274\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:51:17Z","timestamp":1760165477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":46,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13174274"],"URL":"https:\/\/doi.org\/10.3390\/cancers13174274","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2021,8,25]]}}}